Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 15.07.2024 1 Aging (Albany NY) 2 Ann Surg Oncol 3 Arch Esp Urol 1 Asian J Surg 1 Biomater Sci 23 Bladder Cancer 1 Cell Mol Life Sci 1 Clin Chim Acta 1 Crit Rev Anal Chem 1 Curr Med Chem 1 Curr Med Sci 1 Cytometry A 1 Environ Geochem Health 1 Fr J Urol 1 Front Immunol 1 Front Pharmacol 1 Heliyon 1 Hereditas 1 Int Immunopharmacol 1 Int J Biol Sci 1 J Cancer Res Clin Oncol 1 J Magn Reson Imaging 1 J Med Case Rep 1 J Nippon Med Sch 1 J Occup Environ Med 1 J Pathol 1 J Transl Med 1 J Urol 1 J Zhejiang Univ Sci B 1 Jpn J Clin Oncol 1 Med Oncol 1 Med Phys 1 Nutr Cancer 2 Target Oncol 2 Transl Androl Urol 1 Transl Cancer Res 1 World J Methodol 1 World J Psychiatry 2 World J Urol 1 Zhonghua Yi Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aging (Albany NY)

1. JIANG Y, Yu Z, Zheng H, Zhou X, et al
   An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer.
   Aging (Albany NY). 2024;16.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ZHANG M, Wu J, Zhang Y, Shang H, et al
   Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer.
   Ann Surg Oncol. 2024 Jul 12. doi: 10.1245/s10434-024-15725.
   PubMed         Abstract available
   
   
3. WONG CH, Ko IC, Kang SH, Kitamura K, et al
   ASO Visual Abstract: Long-Term Outcomes of Orthotopic Neobladder versus Ileal Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC): Multicenter Results from the Asian RARC Consortium.
   Ann Surg Oncol. 2024;31:5119-5120.
   PubMed        
   
   

   
   Arch Esp Urol

4. CHENG H, Wang R, Lu L, Gong Y, et al
   Bladder Cancer Patients with Elevated SPRR1B Expression Experiencing a Poor Prognosis.
   Arch Esp Urol. 2024;77:554-569.
   PubMed         Abstract available
   
   
5. YORULMAZ EM, Kose O, Ozcan S, Gorgel SN, et al
   Factors Influencing Bladder Perforation during Transurethral Resection of Bladder Cancer: A Comprehensive Analysis.
   Arch Esp Urol. 2024;77:471-478.
   PubMed         Abstract available
   
   
6. PEREZ GONZALEZ S, Heredia-Soto V, Giron de Francisco M, Perez-Fernandez E, et al
   Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review.
   Arch Esp Urol. 2024;77:463-470.
   PubMed         Abstract available
   
   

   
   Asian J Surg

7. CHEN TF, Chen HY, Jiang WL, Li SN, et al
   A rare case of rapid progression from cystitis to bladder cancer.
   Asian J Surg. 2024 Jul 9:S1015-9584(24)01403.
   PubMed        
   
   

   
   Biomater Sci

8. ZHUANG S, Jin X, Cen L, Shao Y, et al
   Encapsulation of hydroxycamptothecin within porous and hollow poly(L-lactide-co-epsilon-caprolactone) microspheres as a floating delivery system for intravesical instillation.
   Biomater Sci. 2024;12:3659-3671.
   PubMed         Abstract available
   
   

   
   Bladder Cancer

9. RADVANYI F, Real FX, McConkey D
   What is a Bladder Cancer Molecular Subtype? - Counterpoint.
   Bladder Cancer. 2023;9:299-304.
   PubMed         Abstract available
   
   
10. ABDELTWAB RM, Yacoub E, Rashad AH, Shohdy KS, et al
    Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets.
    Bladder Cancer. 2023;9:313-322.
    PubMed         Abstract available
    
    
11. MESSING EM
    A New Standard of Care for Bladder Cancer.
    Bladder Cancer. 2023;9:383-385.
    PubMed        
    
    
12. VAN ZUTPHEN M, Kiemeney LALM, Oldenhof UTH, Maurits JSF, et al
    No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort.
    Bladder Cancer. 2023;9:355-363.
    PubMed        
    
    
13. HOGLUND M
    What is a Bladder Cancer Molecular Subtype?
    Bladder Cancer. 2023;9:293-298.
    PubMed         Abstract available
    
    
14. GRAJALES V, Contieri R, Tan WS, Flores M, et al
    Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.
    Bladder Cancer. 2023;9:327-334.
    PubMed         Abstract available
    
    
15. ASIMAKOPOULOS AD, Kochergin M, Colalillo G, Fahmy O, et al
    New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2023;9:237-251.
    PubMed         Abstract available
    
    
16. AZURI W, Jaunarena JH, Camean JJ, Chemi J, et al
    The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Bladder Cancer. 2023;9:227-236.
    PubMed         Abstract available
    
    
17. MESSING EM
    Y Chromosome Loss and Bladder Cancer.
    Bladder Cancer. 2023;9:287-288.
    PubMed        
    
    
18. CHANG E, Hahn NM, Lerner SP, Fallah J, et al
    Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2023;9:271-286.
    PubMed         Abstract available
    
    
19. MENG XY, Wang QL, Shi MJ, Zhang HY, et al
    Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility.
    Bladder Cancer. 2023;9:211-216.
    PubMed         Abstract available
    
    
20. WANG YA, Ranti D, Bieber C, Galsky M, et al
    NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.
    Bladder Cancer. 2023;9:125-139.
    PubMed         Abstract available
    
    
21. ZHANG JH, Starr SL, Chamie K
    Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.
    Bladder Cancer. 2023;9:109-123.
    PubMed         Abstract available
    
    
22. MESSING EM
    Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
    Bladder Cancer. 2023;9:191-192.
    PubMed        
    
    
23. MELGAREJO SEGURA MT, Morales Martinez A, Yanez Castillo Y, Arrabal Polo MA, et al
    Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2023;9:159-166.
    PubMed         Abstract available
    
    
24. MOORE A, Lobaugh SM, Zhang Z, Rosenberg JE, et al
    Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer.
    Bladder Cancer. 2023;9:141-150.
    PubMed         Abstract available
    
    
25. PARE JF, Tabasinezhad M, Grossman A, Atallah A, et al
    Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy.
    Bladder Cancer. 2023;9:175-186.
    PubMed         Abstract available
    
    
26. ALAM SM, Martin A, McLeay MT 2nd, Smith H, et al
    Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2023;9:167-174.
    PubMed         Abstract available
    
    
27. SCHMITZ-DRAGER C, Goebell PJ, Paxinos E, Bismarck E, et al
    Potential of an mRNA-Based Urine Assay (Xpert((R)) Bladder Cancer Detection(1)) in Hematuria Patients - Results from a Cohort Study.
    Bladder Cancer. 2024;10:25-33.
    PubMed         Abstract available
    
    
28. DURANT AM, Lee YS, Mi L, Faraj K, et al
    Effect of Bacille Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer After Prostate Radiotherapy.
    Bladder Cancer. 2024;10:35-45.
    PubMed         Abstract available
    
    
29. HEARD JR, Mitra AP
    Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays.
    Bladder Cancer. 2024;10:71-81.
    PubMed         Abstract available
    
    
30. SOLOWAY MS, Abrahams NA
    Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer.
    Bladder Cancer. 2024;10:93-103.
    PubMed        
    
    
31. MCCONKEY DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, et al
    Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer.
    Bladder Cancer. 2024;10:1-8.
    PubMed        
    
    

    
    Cell Mol Life Sci

32. HUANG G, Liu J, Yu A, Luo C, et al
    Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance of bladder cancer.
    Cell Mol Life Sci. 2024;81:292.
    PubMed         Abstract available
    
    

    
    Clin Chim Acta

33. GAO Y, Zhang X, Wang X, Sun R, et al
    The clinical value of rapidly detecting urinary exosomal lncRNA RMRP in bladder cancer with an RT-RAA-CRISPR/Cas12a method.
    Clin Chim Acta. 2024 Jul 7:119855. doi: 10.1016/j.cca.2024.119855.
    PubMed         Abstract available
    
    

    
    Crit Rev Anal Chem

34. CHENG K, Wan S, Yang JW, Chen SY, et al
    Applications of Biosensors in Bladder Cancer.
    Crit Rev Anal Chem. 2024 Jul 8:1-20. doi: 10.1080/10408347.2024.2373923.
    PubMed         Abstract available
    
    

    
    Curr Med Chem

35. ABAZARI O, Dayati P, Shahidi M, ZavarReza J, et al
    Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis: In-silico and Clinical Studies.
    Curr Med Chem. 2024 Jul 8. doi: 10.2174/0109298673302140240627053904.
    PubMed         Abstract available
    
    

    
    Curr Med Sci

36. WANG L, Wang P, Liu B, Zhang H, et al
    LncRNA MEG3 Inhibits the Epithelial-mesenchymal Transition of Bladder Cancer Cells through the Snail/E-cadherin Axis.
    Curr Med Sci. 2024 Jul 11. doi: 10.1007/s11596-024-2895.
    PubMed         Abstract available
    
    

    
    Cytometry A

37. WEI S, Lei C
    Noninvasive detection for bladder cancer: Quantitative interferometric imaging flow cytometry.
    Cytometry A. 2024 Jul 10. doi: 10.1002/cyto.a.24887.
    PubMed        
    
    

    
    Environ Geochem Health

38. CHUNG YL, Lin MH, Liaw YP, Guo HR, et al
    Dose-response relationship between arsenic in drinking water and mortality of urinary cancers in Taiwan.
    Environ Geochem Health. 2024;46:299.
    PubMed         Abstract available
    
    

    
    Fr J Urol

39. SAINT F, Pasquier D, Villers A, Massa J, et al
    Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France.
    Fr J Urol. 2024 Jul 3:102675. doi: 10.1016/j.fjurol.2024.102675.
    PubMed         Abstract available
    
    

    
    Front Immunol

40. ZHANG X, Pei Z, Ren J, Shi J, et al
    PA-MSHA improves prognosis of patients undergoing radical cystectomy: a retrospective cohort study using inverse probability of treatment weighting.
    Front Immunol. 2024;15:1403302.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

41. XU Z, Zhao Y, Zhang Y, Liu X, et al
    Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment.
    Front Pharmacol. 2024;15:1387647.
    PubMed         Abstract available
    
    

    
    Heliyon

42. LIU J, Zhijin Z, Zhang W, Niraj M, et al
    Urinary exosomes: Potential diagnostic markers and application in bladder cancer.
    Heliyon. 2024;10:e32621.
    PubMed         Abstract available
    
    

    
    Hereditas

43. HAN D, Xiong B, Zhang X, Chen C, et al
    Knockdown of AMIGO2 suppresses proliferation and migration through regulating PPAR-gamma in bladder cancer.
    Hereditas. 2024;161:21.
    PubMed         Abstract available
    
    

    
    Int Immunopharmacol

44. WANG Z, Chen DN, Huang XY, Zhu JM, et al
    Machine learning-based autophagy-related prognostic signature for personalized risk stratification and therapeutic approaches in bladder cancer.
    Int Immunopharmacol. 2024;138:112623.
    PubMed         Abstract available
    
    

    
    Int J Biol Sci

45. HUANG C, Yang Y, Wang X, Chen S, et al
    PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer.
    Int J Biol Sci. 2024;20:3570-3589.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

46. STORMOEN DR, Rohrberg KS, Mouw KW, Orum K, et al
    Similar genetic profile in early and late stage urothelial tract cancer.
    J Cancer Res Clin Oncol. 2024;150:339.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

47. YU R, Cai L, Cao Q, Liu P, et al
    Development and Validation of an MRI-Based Nomogram for Preoperative Detection of Muscle Invasion in VI-RADS 3.
    J Magn Reson Imaging. 2023 Oct 30. doi: 10.1002/jmri.29103.
    PubMed         Abstract available
    
    

    
    J Med Case Rep

48. ISHIDA N, Nagata K, Fukuda J, Oguma Y, et al
    Stereotactic body radiation therapy for multiple lung cancers in a patient with six primary cancers: a case report.
    J Med Case Rep. 2024;18:316.
    PubMed         Abstract available
    
    

    
    J Nippon Med Sch

49. HONDA Y, Sekine T, Kimata R, Motoda N, et al
    Early and Post-Treatment Imaging Findings in Perineural Spread: A Pathway to Diffuse Muscle Metastasis in Recurrent Bladder Carcinoma.
    J Nippon Med Sch. 2024;91:333-338.
    PubMed         Abstract available
    
    

    
    J Occup Environ Med

50. GARIAZZO C, Massari S, Consonni D, Marchetti MR, et al
    Cancer-Specific Mortality Odds Ratios in the Food, Accommodation, and Beverage Activities in Italy.
    J Occup Environ Med. 2024;66:572-579.
    PubMed         Abstract available
    
    

    
    J Pathol

51. SZARVAS T, Reis H
    Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder(dagger).
    J Pathol. 2024;263.
    PubMed         Abstract available
    
    

    
    J Transl Med

52. WU C, Wei X, Huang Z, Zheng Z, et al
    Urinary microbiome dysbiosis is associated with an inflammatory environment and perturbed fatty acids metabolism in the pathogenesis of bladder cancer.
    J Transl Med. 2024;22:628.
    PubMed         Abstract available
    
    

    
    J Urol

53. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 May 17:101097JU0000000000004018. doi: 10.1097/JU.0000000000004018.
    PubMed        
    
    

    
    J Zhejiang Univ Sci B

54. ZENG S, Xing S, Zhang Y, Wang H, et al
    Nano-Bacillus Calmette-Guerin immunotherapies for improved bladder cancer treatment.
    J Zhejiang Univ Sci B. 2024 Jul 9:1-11. doi: 10.1631/jzus.B2300392.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

55. YOKOYAMA M, Chen W, Waseda Y, Fujiwara M, et al
    Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study.
    Jpn J Clin Oncol. 2024;54:822-826.
    PubMed         Abstract available
    
    

    
    Med Oncol

56. CHOU WH, Wang A, Bassale S, Latour E, et al
    Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in elderly patients: a retrospective cohort study.
    Med Oncol. 2024;41:197.
    PubMed         Abstract available
    
    

    
    Med Phys

57. XIONG S, Fu Z, Deng Z, Li S, et al
    Machine learning-based CT radiomics enhances bladder cancer staging predictions: A comparative study of clinical, radiomics, and combined models.
    Med Phys. 2024 Jul 8. doi: 10.1002/mp.17288.
    PubMed         Abstract available
    
    

    
    Nutr Cancer

58. ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
    A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
    Nutr Cancer. 2024 Jul 7:1-9. doi: 10.1080/01635581.2024.2374046.
    PubMed         Abstract available
    
    

    
    Target Oncol

59. GUPTA S, Moon HH, Sridhar SS
    A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Target Oncol. 2024;19:483-494.
    PubMed         Abstract available
    
    
60. UCHIMOTO T, Matsuda T, Komura K, Fukuokaya W, et al
    C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Target Oncol. 2024;19:635-644.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

61. AKINSOLA OA, Talwar R, Baskin A, Luckenbaugh AN, et al
    Use of atezolizumab in bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2024;13:1061-1063.
    PubMed        
    
    
62. LINDSKROG SV, Dyrskjot L
    Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer.
    Transl Androl Urol. 2024;13:1056-1060.
    PubMed        
    
    

    
    Transl Cancer Res

63. CHEN K, Chen S, Wu S, Sun G, et al
    Prognostic value of GARS in bladder cancer and its role in the tumor microenvironment.
    Transl Cancer Res. 2024;13:2825-2846.
    PubMed         Abstract available
    
    

    
    World J Methodol

64. XIANG L, Xie QQ, Xu SS, Ruan WJ, et al
    Association between tobacco exposure and bladder cancer recurrence: A systematic review and meta-analysis.
    World J Methodol. 2024;14:91889.
    PubMed         Abstract available
    
    

    
    World J Psychiatry

65. LU B, Ding M, Xu HB, Yan CY, et al
    Status quo and factors of depression and anxiety in patients with non-muscle invasive bladder cancer after plasma electrocision.
    World J Psychiatry. 2024;14:822-828.
    PubMed         Abstract available
    
    

    
    World J Urol

66. SONG Y, Xu T
    Gender difference of bladder cancer: insights from hormone, anatomy and tumor microenvironment.
    World J Urol. 2024;42:401.
    PubMed        
    
    
67. SANO T, Yoshida T, Nakamoto T, Ohe C, et al
    Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis.
    World J Urol. 2024;42:389.
    PubMed         Abstract available
    
    

    
    Zhonghua Yi Xue Za Zhi

68. WANG MS, Zhang SH, Wang JW, Jia BL, et al
    [Functional analysis of laparoscopic intracorporeal Xing's neobladder in long-term follow-up].
    Zhonghua Yi Xue Za Zhi. 2024;104:2449-2451.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.